NIDA Boss Touts Addiction Studies

Editor's Note: Scientists looking for a crash course in effective communication of their research findings should catch Alan Leshner in action. During recent months, the personable director of the Rockville, Md.-based National Institute on Drug Abuse (NIDA) has been moderating a series of "Town Meetings" in such metropolises as Philadelphia, Dallas, Chicago, and Atlanta. In the keynote talk he gives on the myths and realities of drug abuse and addiction, he juxtaposes graphs and cartoons with a

Written bySteve Bunk
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Editor's Note: Scientists looking for a crash course in effective communication of their research findings should catch Alan Leshner in action. During recent months, the personable director of the Rockville, Md.-based National Institute on Drug Abuse (NIDA) has been moderating a series of "Town Meetings" in such metropolises as Philadelphia, Dallas, Chicago, and Atlanta. In the keynote talk he gives on the myths and realities of drug abuse and addiction, he juxtaposes graphs and cartoons with anecdotes, jokes, and research findings (NIDA funds more than 85 percent of the world's research on health aspects of drug abuse and addiction), keeping large audiences rapt.

Leshner supports his central message-that drug addiction is a chronic, relapsing brain disease-with such ear-catching sound bites as, "We know more about drugs in the brain that we know about anything in the brain." Listeners tend to nod in agreement when he declares, "Drugs hijack the brain." ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies